Delivery Order SPE2DB24D1006-SPE2DB25FCFAC
- Not listed
- The Defense Logistics Agency awarded a $3,381.47 delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on June 20, 2025, with completion expected by June 23, 2025. This firm fixed-price contract represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, aligning with AmerisourceBergen's extensive portfolio of pharmaceutical products supplied...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,681.38 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pens on August 29, 2025, with completion expected by September 2, 2025. This competitively awarded, firm fixed-price delivery order requires fulfillment at AmerisourceBergen's Conshohocken, Pennsylvania location and represents no set-aside designation. Mounjaro is a prescription medication used for diabetes management, consistent with AmerisourceBergen's role...
- The Defense Logistics Agency (DLA) awarded a $2,750.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pens on September 11, 2025, with completion scheduled for September 12, 2025. This non-set-aside award was made competitively and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The pharmaceutical distributor, headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $4,515.92 to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-competitive delivery order represents a firm fixed-price pharmaceutical supply transaction to be performed at the vendor's Conshohocken, Pennsylvania location. Mounjaro is a diabetes medication, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,344.41 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens on September 10, 2025, with completion expected by September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a branded pharmaceutical product used in diabetes management,...
- The Defense Logistics Agency awarded a delivery order valued at $3,437.98 to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 18, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, aligning with AmerisourceBergen's extensive portfolio of...
- The Defense Logistics Agency awarded a delivery order valued at $5,108.64 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pens on August 26, 2025, with an ultimate completion date of August 27, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a prescription medication used in diabetes management, consistent...
- The Defense Logistics Agency awarded a $5,420.32 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Mounjaro 15 mg/0.5 mL pens. This firm fixed-price contract, which is a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, represents a competitively awarded procurement with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency (DLA) awarded a $5,441.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pens on August 22, 2025, with an ultimate completion date of August 25, 2025. This non-competitive, non-set-aside delivery order represents a child contract under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award will be performed at...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCFACDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,822.64 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a prescription medication indicated for diabetes management, reflecting the company's established role as a critical pharmaceutical supplier to federal military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion global pharmaceutical support vehicle running through December 2026. The parent IDC serves as a comprehensive vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products, medical supplies, vaccines, and specialty medications to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's consistent receipt of competitively awarded, non-set-aside contracts across multiple therapeutic domains demonstrates its capacity to meet federal medical procurement requirements and positions it as a key vendor within the federal pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 8/14/25 |